Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Petition for Review.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

JULY 25, 2022

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. She was Founder and Executive Producer of the award-winning future-shaping events series, Creative Innovation Global.

Medicine 52

Medicine Therapy Research and Development Business 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. in/rickdoblin/ [link]. Brian Muraresku. in/ingmargorman/ [link]. in/cgwitowski/ [link]. Bruce Tobin. in/spencer-hawkswell-210a8189/ [link].

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51